Target intelligence / Profile preview

Liver energy balance

Molecular classification
Transcription factor, Receptor, Enzyme, Other
01

Overview

Liver energy balance refers to the physiological maintenance of metabolic homeostasis within the liver, ensuring the coordination of energy acquisition, storage, and utilization in response to nutritional status. This process is primarily regulated by a network of nutrient-sensing nuclear receptors, most notably Peroxisome Proliferator-Activated Receptor alpha (PPARα) and Farnesoid X Receptor (FXR), which serve as sensors for fatty acids and bile acids. These regulators orchestrate the liver's transition between the fed state, focusing on lipogenesis and bile acid control, and the fasted state, characterized by fatty acid oxidation and gluconeogenesis. Dysregulation of liver energy balance is a central feature of metabolic disorders, including non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, leading to excessive lipid accumulation and systemic insulin resistance. Therapeutic strategies aim to restore this balance by utilizing agonists for nuclear receptors or by modulating central metabolic hubs like AMPK. Successfully re-establishing liver energy balance is critical for mitigating hepatic inflammation and preventing the progression to advanced fibrosis or cirrhosis.

Other names
Hepatic energy homeostasisLiver metabolic balanceHepatic nutrient sensingHepatic energy metabolismHepatic energy balance
02

Mechanism of action

Modulation of liver energy balance is achieved by activating or inhibiting key metabolic regulators such as Peroxisome Proliferator-Activated Receptor alpha (PPARα), Farnesoid X Receptor (FXR), and AMP-activated protein kinase (AMPK), which coordinately regulate pathways including fatty acid oxidation, gluconeogenesis, and autophagy.

03

Biological functions

Energy metabolismLipid metabolismGlucose metabolismAutophagyBile acid homeostasis
04

Disease associations

Non-alcoholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)Metabolic dysfunction-associated steatotic liver disease (MASLD)ObesityType 2 diabetes mellitusCholestasis
05

Safety considerations

Pruritus (common with FXR agonists)Gastrointestinal distressPotential for hepatotoxicity with certain agonistsAlterations in LDL cholesterol levelsRisk of cholelithiasis (gallstones)
06

Interacting drugs

Fenofibrate

6 more in the full profile.

07

Biomarkers

Alanine aminotransferase (ALT)Aspartate aminotransferase (AST)Fibroblast growth factor 21 (FGF21)Serum triglyceridesBile acid levelsGlycated hemoglobin (HbA1c)

Beyond the preview

Go deeper on Liver energy balance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liver energy balance.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call